In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.
about
New β-Lactamase Inhibitors in the ClinicCarbapenem resistance: overview of the problem and future perspectivesEmergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature.Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae InfectionsLow Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015.Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif.Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-LactamasesExploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae ST307.Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.Defining the architecture of KPC-2 Carbapenemase: identifying allosteric networks to fight antibiotics resistance
P2860
Q26747150-27E84B08-0089-467F-8CB6-84410599759EQ26767081-20CFF081-85BE-47B9-ADD3-728F74E698DAQ33862098-0BC8D0D4-BA03-4BC1-9FFB-E43B0AB0E0F8Q37023324-A481BFC1-5FE0-4C03-A34C-280291376FA3Q38797485-F2D78591-DB1C-4A5D-A628-E7255C232A90Q39120027-A8C69899-5A73-4759-A92C-D76EDE512224Q40163436-ECB390FB-3574-4902-B667-7A3BCBB4A3FBQ40315371-4FE495F9-3018-4DF9-840A-71D7EAA1D268Q40342728-23D1D1A5-2016-44DB-9128-8FF949DDE62CQ40392497-AA7DD6E6-2E99-43B2-A3E1-0E0A694B32DAQ40392503-77B95D9F-EB7D-4479-8468-0026A899D95EQ40432497-7800FAB3-8394-4596-97A9-139FEF9D1ADBQ40541320-7E4BF5B6-6F13-4761-90B5-5E442B67A396Q41031284-88034F6D-93EE-44A2-937A-0953631B610DQ42319612-DD0EC482-1B95-4A88-80E9-9CA54432FDACQ42358846-57746DEE-4507-42E4-B64E-81DC2D42174BQ45199846-9891E5A1-E07E-48CD-B237-335B0533EAD4Q46267269-CFF7CC40-39F1-4C2A-9213-48DBA47AE905Q46306375-5E745BBF-954A-4658-89B8-BC0E14E274BBQ47269615-DB4594D5-0604-4B37-975B-1850CA253664Q47330235-0249CAC9-9B00-468F-8BF6-B4DBD69D4C16Q52673296-12D738A8-0203-46E1-9EB4-59D91FDABEA2Q53741787-E43DAE13-3C1F-43B0-8DC9-D88E232D8574Q58465760-631DABE6-AE0F-433F-A374-FFE9B842BEB4
P2860
In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@ast
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@en
type
label
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@ast
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@en
prefLabel
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@ast
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@en
P2093
P2860
P356
P1476
In vitro selection of ceftazid ...... ceae with KPC-3 carbapenemase.
@en
P2093
David M Livermore
Dorota Jamrozy
Marina Warner
Nazim Mustafa
Shazad Mushtaq
Wright W Nichols
P2860
P304
P356
10.1128/AAC.00678-15
P407
P577
2015-06-22T00:00:00Z